R
Ross C. Donehower
Researcher at Johns Hopkins University
Publications - 233
Citations - 32588
Ross C. Donehower is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pharmacokinetics & Chemotherapy. The author has an hindex of 72, co-authored 229 publications receiving 28457 citations. Previous affiliations of Ross C. Donehower include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
TL;DR: A Phase I study of CS-682, administered orally five days per week in patients with refractory solid tumor malignancies, found that the recommended phase II dose, given the ease of administration and tolerability, was well tolerated.
Journal Article
Reversibility of High-Affinity Binding of Methotrexate in L1210 Murine Leukemia Cells
TL;DR: The experiments demonstrate the reversibility of methotrexate binding to high-affinity intracellular sites in vitro and are consistent with the hypothesis that residual [ 3 H]-methotrexate persisted in a tightly bound complex with dihydrofolate reductase.
Journal ArticleDOI
Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study
Timothy J. Hobday,Michelle R. Mahoney,Charles Erlichman,Ricardo V. Lloyd,George P. Kim,D. Mulkerin,Joel Picus,Tom R. Fitch,Ross C. Donehower +8 more
TL;DR: 6 month progression-free survival (PFS) rates at 6 months of 30% (carcinoid and ICC) and 10% (ICC) were considered promising and Gefitinib is a small-molecule inhibitor of the EGFR tyrosine kinase domain.
Journal ArticleDOI
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes
Aanika Balaji,Jiajia Zhang,Beatriz Wills,Kristen A. Marrone,Hany Elmariah,Mark Yarchoan,Jacquelyn W. Zimmerman,Khalid Hajjir,Deepti Venkatraman,Deborah K. Armstrong,Daniel A. Laheru,Ranee Mehra,Won Jin Ho,Joshua E. Reuss,Joseph Heng,Paz Vellanki,Ross C. Donehower,Matthias Holdhoff,Jarushka Naidoo +18 more
TL;DR: A notable proportion of ICI-treated patients are hospitalized for irAEs, and these patients have a high demand for multidisciplinary management, which has important implications for inpatient service planning and risk stratification.
Journal ArticleDOI
A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer
Daniel A. Laheru,Gary A. Croghan,Ronald M. Bukowski,Michelle A. Rudek,Wells A. Messersmith,Charles Erlichman,Robert Pelley,Antonio Jimeno,Ross C. Donehower,Joseph Boni,Richat Abbas,Patricia P. Martins,Charles Zacharchuk,Manuel Hidalgo +13 more
TL;DR: In advanced colorectal cancer, 50 mg E KB-569 daily can be safely combined with 1,000 mg/m2 capecitabine twice a day, and a statistically significant increase in plasma levels of 5-fluorouracil for the combination of EKB- 569 and cape citabine may be due to the single-dose versus multiple-dose exposure difference, variability in exposure or a potential drug interaction.